← Back to Clinical Trials
Recruiting NCT05913544

NCT05913544 Short Integrative And Neurocognitive Therapy For Young Adults With Borderline Personality Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05913544
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Nīmes
Condition Borderline Personality Disorder
Study Type INTERVENTIONAL
Enrollment 74 participants
Start Date 2023-11-08
Primary Completion 2026-09

Trial Parameters

Condition Borderline Personality Disorder
Sponsor Centre Hospitalier Universitaire de Nīmes
Study Type INTERVENTIONAL
Phase N/A
Enrollment 74
Sex ALL
Min Age 16 Years
Max Age 25 Years
Start Date 2023-11-08
Completion 2026-09
Interventions
SINTYA

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).

Eligibility Criteria

Inclusion Criteria: * Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale. * High BPD severity level: ZAN-BPD (score ≥ 18/36). * Understand, write and read French. * Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations. * Have signed the informed consent. * For minor patients, have signed the parental consent by at least one holder of parental authority. Exclusion Criteria: * Refusal to participate. * Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance. * Intelligence quotient \< 70. * Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7). * Previous or current participation in specific psychotherapy for BPD. * Subject deprived of liberty (by judicial or administrative decision) and/or protected by law. * Inclusion in another study including psychotherapy for the duration of the study. * Inclusion in a drug RIPH1 study or in a R

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology